Mahajan A, Song W, Walls AC, Mostaghimi A, Micheletti R*, Piette EW* (*co-senior authors) Point-of-Care Risk Factors for Systemic Disease in Patients With Small Vessel Vasculitis of the Skin
, JAMA Dermatol
, 162(1): 2026,94-97
Garg A, Strunk A, Midgette B, Frasier K, Cohn E, Aarts P, Alavi A, Alhusayen R, Bechara BFG, Bettoli V, Brassard A, Brown DP, Chandran NS, Choon SE, Cohen SR, Daveluy S, Del Marmol V, Dellavalle RP, Emtestam L, Farida B, Fernandez-Penas P, Flowers RH, Frew JW, Gebauer KA, Giamarellos-Bourboulis EJ, Goldfarb N, Horváth B, Hsiao JL, Jemec G, Lowes MA, Marzano AV, Matusiak L, Micheletti RG, Oon HH, Orenstein LAV, Ortega-Loayza AG, Paek SY, Pascual JC, Piguet V, Resnik BI, Rosmarin D, Roth GM, Sayed CJ, Silva DLF, Thorlacius L, Tzellos T, van der Zee H, van Straalen K, Ingram JR Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach , JAMA Dermatol, 162(1): 2026,72-79
Martin-Pozo MD, Williams EA, Bonnet KR, Kaffenberger BH, Schlundt DG, Phillips EJ; SJS Survivor Study Recovering From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis , JAMA Dermatol, 162(1): 2026,24-30
Drucker AM, Williams E, Kaffenberger B, Dodiuk-Gad RP, Chren MM, Phillips S, Martin-Pozo M, Goh MS, Ergen E, Micheletti R, Rosenbach M, Yu A, O'Connor A, Mahan K, Phillips EJ Long-term morbidity and quality of life among survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum
, Br J Dermatol.
, 194(1): 2026,161-63
Campbell CN, Krantz MS, Yu A, Phillips EJ; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Survivor Study Collaborators (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Survivor Study Collaborators: Roni Dodiuk Gad, Aaron Drucker, Elizabeth Ergen, Rama Gangula, Michelle Goh, Benjamin Kaffenberger, Dana King, Rebecca Lee, Kelby Mahan, Michelle Martin-Pozo, Robert Micheletti, April O'Connor, Amy Palubinksy, Suman Pakala, Elizabeth Williams, Kristina Williams) HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US , JAMA Dermatol, 161(12): 2025,1258-63
Alpsoy E, Caproni M, Wetter DA, Goebeler M, Levell NJ, Schneider SW, Salavastru C, Velasco ML, Marzano AV, Akyol M, Dutz J, Jachiet M, Kawakami T, Mariotti EB, Maronese CA, Micheletti RG, Monfort JB, Piette W, Ratzinger G, Szepietowski JC, Werth VP, Sunderkötter C Recommendations for the diagnostic work-up of cutaneous small vessel vasculitis - Position Statement of the European Academy of Dermatology and Venereology Vasculitis and Vasculopathy Task Force
, J Eur Acad Dermatol Venereol
: 2025
Li Y, Gibson A, Saeed HN, Tahboub MA, Li D, Ostrov DA, Krantz MS, Mallal SA, Alves E, Chopra A, Choo L, Dodiuk-Gad RP, Kaffenberger B, Drucker AM, Goh MS, Ergen E, Micheletti R, Rosenbach M, Martin-Pozo MD, Gangula R, Williams EA, Yu A, O'Connor A, Mahan K, Kwan JT, Metcalfe D, Rashad R, Shanbhag SS, Pedretti S, Choshi P, Chimbetete T, Selim R, James I, Trubiano JA, Lehloenya R, Peter JG, Phillips EJ HLA-B Alleles With Shared Peptide Binding Specificities Define Global Risk of Co-trimoxazole-Induced Severe Cutaneous Adverse Drug Reactions
, J Allergy Clin Immunol Pract, 13(11): 2025,3042-53
Valdemar Wendelboe Nielsen, Nikolaj Holgersen, Aikaterini I. Liakou, Julia-Tatjana Maul, Alexander Egeberg, Jacob P. Thyssen, Dorra Bouazzi, Gregor B. Jemec MD, Michelle A. Lowes, Afsaneh Alavi, R Hal Flowers, Iltefat Hamzavi, Joslyn Kirby, Robert Micheletti, Christopher Sayed, Simon Francis Thomsen, Haley B. Naik Cardiovascular Risk Assessment in Patients with Hidradenitis Suppurativa: A Multinational Study , Symposium on Hidradenitis Suppurativa Advances 2025, Nashville TN: 2025
Megan Zhao, Benjamin Stone, Douglas S. Jacoby, Nicholas K. Mollanazar, Robert G. Micheletti Cardiovascular Risk Screening and Management in Patients with Hidradenitis Suppurativa , Symposium on Hidradenitis Suppurativa Advances 2025, Nashville TN: 2025
Lorena A. Acevedo-Fontanez, Noah Goldfarb, Robert Micheletti, Alexandra P. Charrow Assessing Dual Biologic/Small Molecule Inhibitor Use among Hidradenitis Suppurativa Specialist
, Symposium on Hidradenitis Suppurativa Advances 2025, Nashville TN: 2025
